Pigmented purpuric dermatosis (PPD) is a rare dermatological disorder characterized by macular rashes that may be purple or brown in color. These lesions are primarily located on the skin and may also be associated with systemic vasculitis. PPD occurs primarily in adults, although cases have been reported in children. The disorder may be due to vascular dysfunction, leading to extravasation of red blood cells and formation of pigmentation in the dermis. Its pathogenesis remains poorly understood, making diagnosis and treatment quite challenging. Thus, pigmented purpuric dermatosis is a multifactorial condition that requires a thorough approach to both diagnosis and therapy.
History of the disease and interesting historical facts
Pigmented purpuric dermatosis was first described in the medical literature in the mid-20th century. Interestingly, similar lesions may have been documented as signs of various diseases over the centuries. In particular, less specific manifestations of purple skin color were documented in the works of ancient Greek and Roman physicians. In the 1990s, several studies showed that diseases with manifestations similar to PPD may have a genetic component, increasing interest in heredity in this context. The introduction of the term pigmented purpuric dermatosis into clinical practice and literature has stimulated more in-depth research and analysis of the pathogenesis of this condition, which has remained in the shadow of more well-known dermatological diseases.
Epidemiology
The epidemiology of pigmented purpuric dermatosis remains poorly understood. Worldwide, the incidence of PPD is reported to be variable and may range from 0.1% to 1% in all dermatological practices. However, given its rarity, the exact numbers may vary across regions and populations. The disease can affect people of any age, but is reported to be most common in people between 40 and 60 years of age. Most cases are reported in countries with national health statistics systems, while the incidence may be underreported in developing countries.
Genetic predisposition to this disease
Genetic factors play an important role in the development of pigmented purpuric dermatosis. It is suggested that some genes involved in the regulation of vascular permeability and inflammatory processes may influence the predisposition to the disease. For example, mutations in genes encoding components of the immune response or the vascular system may increase the risk of developing PPD. Recent studies have identified changes in genes such as IL-6 and TNF-α, which are responsible for the regulation of inflammatory processes. However, the full picture of genetic predisposition to PPD remains unclear and requires further study.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of pigmented purpuric dermatosis. These include:
- Physical factors: Skin trauma or excessive friction can trigger breakouts.
- Chemical factors: Long-term exposure of the skin to certain chemicals may contribute to the development of dermatosis.
- Individual characteristics: previous skin diseases may increase the risk of developing PPD.
- Systemic diseases: Chronic inflammatory diseases such as vasculitis or systemic lupus erythematosus may contribute to the development of PPD.
- Immune disorders: A weakened immune response may increase susceptibility to this disease.
Diagnosis of this disease
Diagnosis of pigmented purpuric dermatosis includes clinical examination, assessment of the patient's medical history, and the use of additional research methods. The main symptoms of the disease may include:
- The appearance of asymmetrical purple or brown rashes on the skin, especially on the shins and thighs.
- Itching or discomfort in the affected area.
- Sensory disturbances in the area of the rash.
Laboratory tests may be used to confirm the diagnosis, including:
- General and biochemical blood analysis.
- Immunological studies to exclude autoimmune diseases.
- Skin biopsy for morphological examination.
Radiological examination is usually not required but may be indicated to evaluate the vascular status. Differential diagnosis should include other disorders associated with purpuric rashes, such as thrombocytopenic purpura, vasculitis, and dermatitis.
Treatment
Treatment for pigmented purpuric dermatosis is aimed at controlling symptoms and minimizing manifestations. General treatment may include:
- Lifestyle changes and elimination of risk factors.
- Emollients for moisturizing and protecting the skin.
Pharmacological treatment may consist of the following groups of drugs:
- Corticosteroids to reduce inflammation and itching.
- Immunosuppressants in severe cases when traditional treatments are ineffective.
- Antihistamines to relieve itching.
Surgery may be required for larger lesions or secondary infections that require drainage or removal of the affected tissue. Other treatments may include physical therapy and the use of creams with antiseptic and anti-inflammatory properties.
List of medications used to treat this disease
The main drugs used to treat pigmented purpuric dermatosis include:
- Prednisolone
- Methotrexate
- Hydroxychloroquine
- Diprospan
- Loratadine
Disease monitoring
Monitoring of pigmented purpuric dermatosis involves regular visits to a dermatologist to assess the condition of the skin and identify possible complications. Control stages may include:
- Periodic laboratory tests to assess liver and kidney function, especially when using immunosuppressants.
- Evaluation of the effectiveness of therapy with treatment adjustments if necessary.
- Prevention of exacerbations taking into account identified risk factors.
The prognosis with adequate treatment is favorable in most cases, but complications such as infectious processes, fibrosis or other skin changes are possible.
Age-related features of the disease
Pigmented purple dermatosis can manifest itself differently in different age groups. In children, the disease can be acute, with vivid clinical symptoms, while in adults, the manifestations can be more hidden and chronic. Elderly patients are more likely to encounter dermatosis against the background of other diseases, such as diabetes or hypertension, which can complicate its course and diagnosis. It is also worth considering that in children, heating and the second time requires more careful attention to potential triggers.
Questions and Answers
- What is the main cause of pigmented purpuric dermatosis? The underlying cause is not yet known, but it is thought to be a multifactorial disorder involving vascular permeability and immune dysfunction.
- How is this disease diagnosed? Diagnosis includes clinical examination, medical history, laboratory tests and, if necessary, skin biopsy.
- What treatment is recommended for pigmented purpuric dermatosis? Treatment may include corticosteroids, emollients, antihistamines, and, in severe cases, immunosuppressants.
- Can the disease go away on its own? In some cases, the disease may regress on its own, but observation and treatment are recommended to prevent possible complications.
- Is there a genetic predisposition to this disease? Yes, certain genetic mutations may increase the risk of developing pigmented purpuric dermatosis, but the exact causes remain poorly understood.
